Therapy of 17 cases of idiopathic thrombocytopenia purpura by amifostine.
- Author:
Hui FAN
1
;
Hong-Li ZHU
;
Su Xia LI
;
Xue-Chun LU
;
Yang YANG
;
Shan-Qian YAO
Author Information
1. Department of Geriatric Hematology, PLA General Hospital, Beijing 100853, China.
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Age Factors;
Aged;
Aged, 80 and over;
Amifostine;
adverse effects;
therapeutic use;
Female;
Humans;
Infusions, Intravenous;
Male;
Middle Aged;
Purpura, Thrombocytopenic, Idiopathic;
drug therapy;
Treatment Outcome
- From:
Journal of Experimental Hematology
2008;16(1):192-196
- CountryChina
- Language:Chinese
-
Abstract:
The objective of this study was to explore the effect of amifostine (AMF) in treating patients with idiopathic thrombocytopenic purpura (ITP) and its adverse effects. 17 ITP patients (aged from 13 to 92, mean 65 years) were treated with AMF and their therapeutic regimen was following: 0.4 g AMF was dissolved in 100 ml physiological saline, the intravenous drop was performed at day and lasted 5 days per week, with interval 2 days, 4 weeks were considered as a course of treatment. The results showed that the normal counts of platelets were observed in 17 ITP patients after 1 course of treatment, and remained unchanged for 2 months following stop of therapy. In that time, no any drugs such as hormonal preparation, gamma-globulin, blood transfusion and so on were given in all treated patients, the main adverse effect of AMF was discomfort in digestive system that all patients could endure. Therefore, the patient's life quality was obviously improved. It is concluded that the AMF has been initially and successfully used to treat ITP patients with positive response, and may be considered as a safe-effective drug for treating old patients with ITP, but the long-term effect and pharmacological mechanism of this drug needs further evaluation.
